Exelixis, Inc. (NASDAQ:EXEL) Holdings Decreased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,273,620 shares of the biotechnology company's stock after selling 33,071 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.15% of Exelixis worth $84,950,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Covestor Ltd raised its position in Exelixis by 5.7% in the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company's stock valued at $164,000 after purchasing an additional 341 shares during the period. Resonant Capital Advisors LLC lifted its holdings in Exelixis by 3.6% in the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company's stock worth $309,000 after buying an additional 477 shares in the last quarter. Cornercap Investment Counsel Inc. increased its holdings in shares of Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company's stock valued at $1,135,000 after acquiring an additional 539 shares during the last quarter. Creative Planning lifted its stake in Exelixis by 0.8% during the second quarter. Creative Planning now owns 71,700 shares of the biotechnology company's stock worth $1,611,000 after purchasing an additional 548 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company's stock worth $515,000 after purchasing an additional 609 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other news, Director George Poste sold 30,000 shares of the firm's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the completion of the sale, the director now directly owns 169,020 shares of the company's stock, valued at $5,746,680. This trade represents a 15.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Dana Aftab sold 1,162 shares of the business's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 279,736 shares of company stock valued at $9,308,410 in the last quarter. Insiders own 2.85% of the company's stock.

Analyst Ratings Changes

EXEL has been the subject of several research reports. TD Cowen lifted their price target on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a report on Monday, October 21st. Truist Financial increased their price target on Exelixis from $33.00 to $38.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Stephens boosted their price objective on Exelixis from $23.00 to $29.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 30th. JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 target price on shares of Exelixis in a research report on Friday, October 11th. Finally, Guggenheim raised their target price on Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and an average price target of $31.44.

Exelixis Stock Performance

Shares of EXEL stock traded down $0.52 during mid-day trading on Thursday, hitting $35.93. 1,780,888 shares of the stock traded hands, compared to its average volume of 2,072,248. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $36.73. The company's 50-day simple moving average is $30.44 and its 200-day simple moving average is $25.90. The firm has a market cap of $10.26 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same period in the previous year, the company earned $0.10 earnings per share. Exelixis's revenue was up 14.3% compared to the same quarter last year. Analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.